164 related articles for article (PubMed ID: 37101199)
1. TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
Ragu ME; Lim JMC; Ng PS; Yip CH; Rajadurai P; Teo SH; Pan JW
Breast Cancer Res; 2023 Apr; 25(1):48. PubMed ID: 37101199
[TBL] [Abstract][Full Text] [Related]
2. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences.
Pan JW; Zabidi MMA; Ng PS; Meng MY; Hasan SN; Sandey B; Sammut SJ; Yip CH; Rajadurai P; Rueda OM; Caldas C; Chin SF; Teo SH
Nat Commun; 2020 Dec; 11(1):6433. PubMed ID: 33353943
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
4. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
6. Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
Pan JW; Ragu M; Chan WQ; Hasan SN; Islam T; Teoh LY; Jamaris S; See MH; Yip CH; Rajadurai P; Looi LM; Taib NAM; Rueda OM; Caldas C; Chin SF; Lim J; Teo SH
Breast Cancer Res; 2024 Apr; 26(1):67. PubMed ID: 38649964
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
8. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
[TBL] [Abstract][Full Text] [Related]
9. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
10. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
12. Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.
Joshi H; Bhanot G; Børresen-Dale AL; Kristensen V
Br J Cancer; 2012 Nov; 107(10):1722-8. PubMed ID: 23079576
[TBL] [Abstract][Full Text] [Related]
13. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
14. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
[TBL] [Abstract][Full Text] [Related]
15. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Lin CH; Chen IC; Huang CS; Hu FC; Kuo WH; Kuo KT; Wang CC; Wu PF; Chang DY; Wang MY; Chang CH; Chen WW; Lu YS; Cheng AL
Sci Rep; 2015 Dec; 5():17879. PubMed ID: 26671300
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
17. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
19. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
